Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis

Anton L. Pozniak, Joel E. Gallant, Edwin DeJesus, Jose R. Arribas, Brian Gazzard, Rafael E. Campo, Shan Shan Chen, Damian McColl, Jeffrey Enejosa, John J. Toole, Andrew K. Cheng

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with fixed-dose zidovudine (ZDV)/lamivudine (3TC) and EFV through 48 weeks. Results through a 96-week extension phase are presented. METHODS: In this randomized, open-label, noninferiority trial, 517 antiretroviral-naive HIV-infected patients received TDF, FTC, and EFV (TDF + FTC + EFV) or ZDV/3TC and EFV (ZDV/3TC + EFV). The primary endpoint was the proportion of patients with an HIV RNA level

Original languageEnglish (US)
Pages (from-to)535-540
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume43
Issue number5
DOIs
StatePublished - Dec 2006

Keywords

  • Antiretroviral naive
  • Emtricitabine
  • Lamivudine
  • Lipoatrophy
  • Tenofovir
  • Zidovudine

ASJC Scopus subject areas

  • Virology
  • Immunology

Fingerprint

Dive into the research topics of 'Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis'. Together they form a unique fingerprint.

Cite this